Expanded access to upadacitinib treatment
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Digestive system, Genetic & congenital, Heart & circulation, Immune system & allergy, Infections, Skin clinical trials.
This trial provides early access to a medication called upadacitinib for people who have no other suitable treatment options and cannot join a clinical trial. Upadacitinib may help manage certain conditions when standard treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must not have any other suitable treatment options available.
- You must not be eligible for an ongoing clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study looks at how well upadacitinib treats enthesitis (pain where tendons or ligaments attach to bone) in people with psoriatic arthritis. Researchers will use ultrasound to measure improvement. The trial is for adults who have already tried at least one biologic drug, including an anti-TNF, without success.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
This trial tests a medication called upadacitinib for people hospitalized with a severe ulcerative colitis flare. It could help control inflammation and reduce symptoms.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.